Navigation Links
China Sky One Medical, Inc. Signs Distribution Agreement with Harbin Baolong Pharmaceutical Company
Date:7/15/2008

HARBIN, China, July 15 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Amex: CSY), a leading fully integrated pharmaceutical company producing external use, over- the-counter drugs in the People's Republic of China ("PRC"), announced today that it signed an agreement with Harbin Baolong Pharmaceutical Company on July 12 to distribute the Company's prescription drugs.

China Sky One, which has a history of producing external use and over-the- counter drugs, has recently acquired pharmaceutical companies that develop and produce prescription drugs. As a result, prescription drugs manufactured by China Sky One have doubled and now make up approximately 30% of its total product lines. Harbin Baolong Pharmaceutical Company, which has an extensive distribution network for prescription drugs in China, achieved revenues of in excess of RMB 500 million (USD $73.1 million) in each of the last two years.

The agreement, which initially runs over five years, has a total estimated value of approximately RMB 61.5 million (USD $ 9 million.) To date, China Sky One has been selling five of its prescription drugs through Baolong's distribution network, which it expects will generate sales of approximately RMB 20.5 million (USD $3 million) from August 2008 to December 2008.

"We are excited to be cooperating with Harbin Baolong Pharmaceutical Company," said Mr. Yan-Qing Liu, Chairman, CEO and President of China Sky One Medical, Inc. "We are confident that our move into the prescription drug market via Baolong's strong distribution channel represents a solid opportunity for future growth and can ultimately help us expand our market share and increase profitability going forward."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR") and Harbin First Bio- Engineering Company Limited ("First"), the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

For more information, please contact:

Company Contact:

China Sky One Medical, Inc.

Ms. Yanwei Zhang, Board Secretary

Tel: +86-451-5399-4064

Email: cntiandiren@yahoo.com.cn

Investor Relations Contact:

CCG Investor Relations

Mr. Crocker Coulson, President

Tel: +1-646-213-1915

Email: crocker.coulson@ccgir.com

Mr. Richard Micchelli, Financial Writer

Tel: +1-646-454-4516

Email: richard.micchelli@ccgir.com

Web: http://www.ccgir.com


'/>"/>
SOURCE China Sky One Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AmeriCares Purchases 2nd BLU-MED Deployable Field Hospital for China Earthquake Relief
2. Closing coal-burning power plant in China and improved cognitive development in children
3. China Kangtai Cactus Biotech Inc. Launches Cactus Cattle Feed and Cactus Fish Feed
4. AmeriCares Meets Long-Term Health Needs of Disaster Victims in China and Myanmar
5. Chindexs United Family Healthcare Launches ChinaHealthWatch.org - A global resource for travelers to China
6. China Medicine Releases White Paper on Developing Recombinant Aflatoxin-Detoxifizyme
7. Chindex International, Inc. Announces Receipt of Key Regulatory ApprovalsChina SFDA Certificates Received Include Intuitive Surgical daVinci S
8. China Improves Safety Management on Imported Foods in Preparation for Olympic Games
9. AMDL Signs Letter of Intent to Purchase China-Based Pharmaceutical Distribution Company
10. Cynosure Expands Presence in China with the Opening of Sales Office in Beijing
11. Golden Meditech Pioneers into Chinas Hospital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a missionary ... Journey: From the Mountains to the Mission Field” is the creation of published author, ... ages and currently teaches a class of ladies at her church, which she has ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Leading pediatric ... peers in Washington, D.C., for the 49th Congress of the International Society of ... Vice President of the Center for Cancer and Blood Disorders at Children’s ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2017 The Rebound mobile app is poised to ... the tide of prescription drug addiction. The app empowers users ... and stepping down their dosage in a safe, controlled manner ... 2017; the first 100,000 people to sign up will enjoy ... ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/19/2017)... Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company ... destruction of targeted tissues, announced three leadership team developments today:   ... PhD ... ... Veteran medical device executive Josh ...
Breaking Medicine Technology: